

**Question for written answer E-003561/2025
to the Commission**
Rule 144
Billy Kelleher (Renew)

Subject: Equal access to treatment and funding for neurodegenerative diseases

Parkinson's disease is the fastest growing neurological condition and the second most common neurodegenerative disease after Alzheimer's. An estimated 1.2 million people are affected by Parkinson's disease in Europe. In Ireland alone there are approximately 18 000 people living with Parkinson's. Furthermore, neurological illnesses account for more healthcare spending in Europe than cardiovascular disease, cancer and diabetes together, yet shortcomings in healthcare for Parkinson's and other neurodegenerative diseases persist.

1. Given the prominence of neurodegenerative disease in Europe and the fact this is expected to increase in the coming years as a result of population ageing, does the Commission consider neurodegenerative diseases a priority in its work on the EU Health Union?
2. What measures will the Commission take to ensure fair and equal access to treatment for Parkinson's disease and other neurodegenerative conditions across the EU? In Ireland, for example, there are on average 1.3 neurologists per 100 000 people, compared to the EU average of 9.

Submitted: 16.9.2025